Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 8

    1.

    Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

    Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.

    Cancer. 2011 Dec 2. doi: 10.1002/cncr.26655. [Epub ahead of print]

    PMID:
    22139894
    [PubMed - as supplied by publisher]
    2.

    IL-6 and ovarian cancer--letter.

    Locasale JW, Zeskind B.

    Clin Cancer Res. 2011 Dec 15;17(24):7837; author reply 7838. Epub 2011 Dec 6. No abstract available.

    PMID:
    22147939
    [PubMed - in process]
    3.

    Error occurred: cannot get document summary

    PMID:
    22147938

    4.

    Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

    Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

    Clin Cancer Res. 2012 Feb 1;18(3):869-81. Epub 2011 Dec 5.

    PMID:
    22142828
    [PubMed - indexed for MEDLINE]
    5.

    Disparities in hospice care among older women dying with ovarian cancer.

    Fairfield KM, Murray KM, Wierman HR, Han PK, Hallen S, Miesfeldt S, Trimble EL, Warren JL, Earle CC.

    Gynecol Oncol. 2012 Apr;125(1):14-8. Epub 2011 Dec 1.

    PMID:
    22138230
    [PubMed - in process]
    6.

    Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.

    Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI.

    Gynecol Oncol. 2012 Mar;124(3):563-8. Epub 2011 Dec 1.

    PMID:
    22138229
    [PubMed - indexed for MEDLINE]
    7.

    Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study.

    Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, Molmans BH, Hollema H, Bart J, Drijfhout JW, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW.

    Int J Cancer. 2011 Dec 3. doi: 10.1002/ijc.27388. [Epub ahead of print]

    PMID:
    22139992
    [PubMed - as supplied by publisher]
    8.

    A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

    Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

    Oncogene. 2011 Dec 5. doi: 10.1038/onc.2011.539. [Epub ahead of print]

    PMID:
    22139083
    [PubMed - as supplied by publisher]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk